Skip to content

Search Results

No Matching Results

    Recently Viewed


      HomeMedia CenterPress releases Medical technologiesDePuy Synthes’ VELYS Robotic-Assisted Solution Paves the Way For Next Generation Knee Replacement Surgery In Australia With The First Clinical Case At Mater Hospital In Sydney

      DePuy Synthes’ VELYS Robotic-Assisted Solution Paves the Way For Next Generation Knee Replacement Surgery In Australia With The First Clinical Case At Mater Hospital In Sydney

      Patients at Sydney’s Mater Hospital are the first in Australia to experience the next generation in robotic assisted surgery.
      Mater’s surgical team trained on the VELYSTM Robotic-Assisted Solution using the Johnson & Johnson Institute’s first-of-its-kind in Australia Mobile Training Lab and Virtual Reality technology.
      VELYS Robotic-Assisted Solution helps address challenges cited with robotic assisted technologies on operational efficiencies by helping to simplify surgeons’ existing workflow.[i][ii]

      Share Article
      share to

      13 Dec, Sydney: DePuy Synthes* in Australia, the orthopaedics business unit of Johnson & Johnson, today announced that the first clinical cases in Australia with the VELYS™ Robotic-Assisted Solution were undertaken at The Mater Hospital Sydney. The VELYS Robotic-Assisted Solution is indicated for use with the ATTUNE® Knee System for total knee arthroplasty.

      Dr. Matt Lyons, orthopaedic surgeon at The Mater Hospital Sydney, said, “Our surgical team has been anticipating the arrival of the VELYS Robotic-Assisted Solution at the Mater since it first gained approval in Australia. Being able to plan patient-specific surgery tailored to each patient’s individual anatomy with the VELYS Robotic-Assisted Solution lets us visualise and predict joint stability to support optimal patient outcomes.”

      Ben Travers, Vice President of DePuy Synthes Australia, Johnson & Johnson Medical Pty Ltd, said, “These cases represent a historic first step for patients as we advance next generation surgery with Australia’s first ever clinical use of the VELYS™ Robotic-Assisted Solution. The Mater Sydney’s adoption of our innovative surgical technology is only the beginning as we strive to improve patient outcomes through state-of-the-art digital surgery. We look forward to more patients benefiting from the VELYS Robotic-Assisted Solution in hospitals around Australia.”

      The VELYS Robotic-Assisted Solution is a first-of-its-kind operating table mounted solution that adapts to the surgeon’s workflow. It utilises advanced planning capabilities, proprietary technology, and a next generation design to help surgeons accurately resect bones that align and position the implant relative to the soft-tissue during total knee replacement without the need for pre-operative imaging. The efficient and compact design integrates into any operating room and does so with a much smaller footprint, at less than half the size of some other robotic-assisted solutions.i,ii
      The VELYS Robotic-Assisted Solution provides:

      • Valuable Insights: Gap balance data designed to help surgeons visualise and predict joint stability
      • Versatile Execution: Intuitive, integrated design intended to give surgeons the control they’re used to while optimising daily OR flow[i]
      • Verified Performance: Designed to provide accurate, consistent plan execution supporting the ATTUNE Knee in providing better patient outcomes[ii],[iii],[iv],[v]

      The arrival of the VELYS Robotic-Assisted Solution at the Mater Sydney is accompanied by the Johnson & Johnson Institute’s first-of-its-kind in Australia Mobile Training Lab, which made training even more accessible to the Mater’s surgical team. The VELYS Mobile Lab provides on-site access to next-generation hands-on training, virtual reality-based operating environments, and real-time collaboration with the global surgical community, all of which is designed to equip the Mater’s orthopaedic surgeons to be proficient with the VELYS Robotic-Assisted Solution.

      Dr. Lyons added, “Having access to the VELYS Mobile Lab nearby accelerated our training process significantly and enabled us to get our teams up and running on this new technology, quickly.”

      The VELYS Robotic-Assisted Solution is part of the broader VELYS Digital Surgery Platform of connected technologies powered by data insights and designed to elevate the orthopaedic experience for patients, surgeons, and their teams across the entire continuum of care, from pre-operative to post-operative.

      For more information on VELYS Robotic-Assisted Solution or for media to view the Mobile Lab for themselves, please contact David Sims for further information. Healthcare providers can access more information on VELYS Robotic-Assisted Solution via the website .

      About DePuy Synthes:
      DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement for the millions of patients we serve. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery and sports medicine, in addition to the VELYS™ Digital Surgery portfolio, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide.

      Building on our proud product innovation and legacy of industry firsts, we are reimagining the orthopaedic landscape with new advancements in medical technologies and digital surgery across the entire continuum of care to Keep People Moving today and tomorrow. For more information, visit

      *DePuy Synthes represents the products and services of Johnson & Johnson Medical Pty Ltd and its affiliates.

      About Johnson & Johnson Institute:
      The Johnson & Johnson Institute educates more than 125,000 health care professionals each year around the world. Education efforts span 25 locations and online modules, encompassing a variety of specialties, including surgical oncology, cardiology and electrophysiology, obesity, ophthalmic and orthopaedic diseases.

      About Johnson & Johnson Medical Devices Companies:
      At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.

      Cautions Concerning Forward-Looking Statements
      This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the VELYSTM Digital Surgery Mobile Lab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Medical Pty Ltd and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

      [1] RIO Technical User Guide (February 24, 2021). Internal Report 103732371. (As cited in The VELYS™ Robotic-Assisted Solution versus Mako® A comparison of system compactness)
      [1] VELYS Robotic-Assisted Solution Operation Dimension (February 24, 2021). Internal Report 103486302. (As cited in The VELYS™ Robotic-Assisted Solution versus Mako® A comparison of system compactness)
      [1] ser experience evaluation of the VELYS Robotic-Assisted Solution for total knee (July 2020). Internal Report 103744839.
      [1] Doan G, Curtis P, Wyss J, Clary C. Resection Accuracy Improved during Robotic-Assisted Total Knee Arthroplasty – a Cadaveric Study. Internal Report 103720852.
      [1] Hamilton W, Brenkel I, Barnett S, et al. Comparison of P.F.C. SIGMA to ATTUNE: A Prospective, Multicenter Study. Podium Presentation at the Closed Meeting of the Knee Society, Sept 2018, St Louis, MO, USA. 2018.
      [1] Fisher D, Parkin D. Optimizing the Value of Your Patients’ TKA: How to Leverage Data from Patient Reported Outcomes, Becker’s Hospital Review, webinar recording, Oct 2019,, last accessed 10-18-19.
      [1] Ranawat CS, White PB, West S, Ranawat AS. Clinical and Radiographic Results of ATTUNE and PFC SIGMA Knee Designs at 2-Year Follow-Up: A Prospective Matched-Pair Analysis. J Arthroplasty 2017; 32:431-6.

      Media Contact
      David Sims
      Johnson & Johnson Medical Australia & New Zealand
      M: +61 (0)409 928 209

      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.